Purdue Pharma and OxyContin

Purdue Pharma and OxyContin

How the Sackler family launched the opioid epidemic.

---

The drug

Oxycodone is a semi-synthetic opioid first synthesized in Germany in 1916. It is approximately 1.5 to 2 times more potent per milligram than morphine. Purdue Pharma's pre-OxyContin product MS Contin — controlled-release morphine, sold from 1984 — had established the company's expertise in extended-release opioid formulations.

OxyContin's distinguishing feature was the Contin time-release matrix combined with oxycodone's higher potency. A single 80mg OxyContin tablet contained approximately 80mg of oxycodone — at a time when typical oral oxycodone (in Percocet, etc.) was dosed at 5mg per tablet. The 12-hour controlled-release was designed for chronic pain management.

The FDA-approved label included the statement that the controlled- release "is believed to reduce the abuse liability of the drug." The basis for this claim was pharmacological: a slow-release formulation would, in theory, deliver oxycodone gradually rather than producing the rapid blood-concentration peak associated with the euphoric effect (and, by inference, with the abuse potential). The label language was inserted by the FDA reviewer Curtis Wright on the basis of this inference. There was no clinical trial of abuse liability prior to approval.

The pharmacological inference was wrong. OxyContin tablets could be crushed and snorted, dissolved and injected, or chewed — each of which delivered the entire 12-hour dose at once. By 2000, abuse of crushed OxyContin had emerged as a significant clinical pattern in Appalachia, the Pacific Northwest, and pockets of New England.

The marketing

The OxyContin marketing campaign, beginning January 1996, was the most aggressive new-drug launch in U.S. pharmaceutical history to that point. The components:

Sales force expansion. Purdue grew its sales force from 318 in 1996 to 671 by 2000. Each representative carried a portfolio that included OxyContin alongside Purdue's other products.

Physician identification. Purdue used the IMS Health prescriber database — which sells aggregated physician-prescribing information to pharmaceutical companies — to identify "high- prescribing" physicians for opioids. The sales force concentrated on these physicians, particularly primary-care doctors who were not pain specialists.

Continuing-medical-education funding. Purdue funded continuing- medical-education courses on pain management, often through third- party consortia. The courses emphasized the under-treatment of chronic pain and downplayed addiction risk.

Direct-to-physician promotion. Purdue sales representatives made approximately 700,000 in-person physician visits between 1996 and 2010. Each visit involved promotional materials, samples (initially), and "patient starter coupons" that allowed patients to receive an initial prescription at no charge.

Performance bonuses. Sales representatives were compensated heavily on a commission-and-bonus structure tied to OxyContin prescription growth. Purdue's internal records (released in discovery) showed total sales-force performance compensation of approximately $700 million between 1996 and 2001.

The "less than 1%" claim. This was the centerpiece. The 1980 NEJM letter by Jane Porter and Hershel Jick — five sentences in the journal's Correspondence section — had reported that, in a review of 11,882 hospitalized inpatients who had received any opioid medication for any duration, only 4 had subsequently developed addiction. The letter was, in retrospect, neither a study nor a finding suitable for the generalization Purdue made of it. It was a single observational note about an in-patient population.

Purdue's promotional materials cited the letter approximately 600 times across the next 20 years, characterizing it as scientific support for the claim that the addiction risk of properly prescribed opioid medication was less than 1 percent. The characterization was repeated by Purdue's funded continuing-medical- education materials, by physicians who attended those courses, and by patients who were prescribed OxyContin on the strength of those materials.

Where the epidemic landed

The geographic distribution of the OxyContin-era opioid crisis was not uniform. It concentrated in specific regions:

• Central Appalachia: West Virginia, eastern Kentucky, southwestern Virginia, southern Ohio. The region had high rates of disability-related chronic pain (mining injuries, manufacturing workforce), elevated Medicaid coverage, and dense networks of family-practice physicians.
• Pacific Northwest: parts of Oregon and Washington, particularly rural counties.
• New England: Maine, New Hampshire, Vermont, Massachusetts.
• Florida: which by the mid-2000s had become the U.S. center of "pill mill" operations — pain-management clinics that dispensed large quantities of OxyContin to out-of-state patients.

By 2010, the U.S. was consuming approximately 80% of the world's prescription opioid supply despite having approximately 5% of the world's population. The cause was not exclusively OxyContin — the broader opioid prescribing pattern across U.S. medicine had shifted in the late 1990s — but OxyContin was the leading-brand product that anchored the market.

The crisis evolved through three identifiable waves:

1. Prescription opioids (1996-2010). OxyContin and similar sustained-release products were the dominant agents. CDC prescription-opioid deaths peaked at approximately 16,917 in 2017.

2. Heroin (2010-2014). When Purdue reformulated OxyContin in August 2010 to be abuse-deterrent (the "OP" tablet that was harder to crush), many opioid-dependent users shifted to heroin — cheaper and equally available. CDC heroin deaths rose from approximately 3,036 in 2010 to 15,482 by 2017.

3. Synthetic opioids — fentanyl (2013-present). Illicitly- manufactured fentanyl entered the U.S. drug supply primarily from Chinese precursor chemicals processed in Mexican laboratories. CDC fentanyl-involved deaths rose from approximately 2,628 in 2013 to over 73,000 in 2022.

The wave analysis, originally articulated by CDC epidemiologists in 2017, characterizes the contemporary opioid crisis as having originated in the OxyContin-era prescription environment even though by 2022 the immediate cause of death was overwhelmingly fentanyl.

The 2007 plea

The first major U.S. legal action against Purdue Pharma came in May 2007. The U.S. Attorney for the Western District of Virginia, John Brownlee, filed a criminal information against Purdue Pharma and three of its top executives — Michael Friedman (CEO), Paul Goldenheim (Chief Medical Officer), and Howard Udell (General Counsel) — alleging misbranding under the Federal Food, Drug, and Cosmetic Act.

The case was based on Purdue's pre-2001 marketing of OxyContin's abuse liability — specifically, on the representation that OxyContin had less abuse potential than other immediate-release opioids. The Brownlee investigation had assembled documentary evidence from Purdue's internal communications showing executives had been aware, by no later than 2000, that crushed OxyContin was being abused at significant rates.

The plea agreement was entered on May 10, 2007. Purdue pleaded guilty to felony misbranding (one count, $470 million in fines) and the three executives pleaded guilty to misdemeanor misbranding (personal fines and probation, no incarceration). The total amount Purdue paid was $634.5 million.

The Brownlee prosecution had developed evidence supporting more serious felony charges including fraud and obstruction. The Bush Justice Department directed Brownlee to accept the misdemeanor plea on the personal charges. The pressure on Brownlee was subsequently documented in 2018 Congressional testimony.

The bankruptcy and the Harrington decision

By 2018, Purdue Pharma faced lawsuits from approximately 2,600 plaintiffs — 49 U.S. states, more than 1,500 cities, counties, and tribes, and a growing private personal-injury MDL.

In September 2019, Purdue filed for Chapter 11 bankruptcy protection in the Southern District of New York. The bankruptcy process became the central forum for resolving the multi-plaintiff litigation.

The 2020 federal plea agreement (negotiated separately) committed Purdue to:

• A guilty plea to three felony charges (fraud and kickback violations).
• $8.3 billion in penalties and forfeitures.
• A conversion of Purdue Pharma into a public benefit company.

The 2022 state attorneys general settlement separately committed the Sackler family to:

• A personal payment of $6 billion across multiple years.
• Surrender of ownership of Purdue.
• Personal-injury releases preventing any future individual claims against the family by claimants who had received bankruptcy-distribution funds.

It was the personal-injury releases that became the legal flash point. On June 27, 2024, the U.S. Supreme Court ruled in Harrington v. Purdue Pharma L.P. (5-4, Justice Gorsuch writing for the majority) that the U.S. Bankruptcy Code did not authorize non-debtor third-party releases — meaning that the Sackler family, which had not personally filed for bankruptcy, could not be released from individual claims through the Purdue bankruptcy.

The 2022 settlement was struck down. As of mid-2026, the renegotiated settlement structure is still being worked out. The Sackler family's wealth, by independent estimates, exceeds $11 billion.

The cast

What we still don't know

The full Sackler financial accounting. The family's withdrawals from Purdue Pharma between 1995 and 2018 have been estimated at $10.7 billion (bankruptcy-filing declarations) to higher figures. The forensic-accounting questions remain partially open in the post-Harrington renegotiation.

The full McKinsey-Purdue relationship. McKinsey's settlement ($573 million in 2021) addressed its role as a sales-strategy consultant 2004-2018. The internal documents released in that settlement include the partially-redacted "Toppling Dominos" 2017 memo. The full content of McKinsey's strategic recommendations to Purdue across the relationship has not been comprehensively disclosed.

The opioid-attribution apportionment. The fraction of the overall opioid-crisis death toll attributable to OxyContin specifically (versus other prescription opioids, heroin, fentanyl) has been the subject of multiple expert-witness analyses with divergent conclusions. The methodologically careful work places OxyContin's contribution at 15-25% of overall crisis-attributable mortality. The methodologically optimistic figures (often offered by Purdue) place it lower; the methodologically pessimistic figures place it higher.

The post-Harrington settlement. As of mid-2026, the Sackler family's exposure to individual claims is being renegotiated following the June 2024 Supreme Court ruling.

Why this is a "confirmed" case

The Purdue/Sackler/OxyContin case is one of the most comprehensively documented corporate-misconduct cases in modern U.S. history. The 2007 plea agreement, the 2020 federal plea, the 2019 bankruptcy filings, the McKinsey 2021 settlement, and the 2024 Supreme Court ruling collectively constitute an extensive formal record. The internal documents are largely on public record through the 2019-2024 discovery process.

What is sometimes still misunderstood — by general audiences whose exposure came through Dopesick (Hulu, 2021) or Empire of Pain (Keefe, 2021) — is the scale of the consequences. 700,000 American deaths is not a metaphor. The cumulative U.S. opioid death toll from 1999 to 2023 is comparable to all American military deaths in all U.S. wars combined (approximately 1.4 million).

Sources

Primary documents:

1. United States v. Purdue Frederick Company, Inc., et al. — Federal plea agreement, U.S. District Court for the Western District of Virginia, May 10, 2007. $634.5 million.
2. United States v. Purdue Pharma L.P. (and related entities) — Federal plea agreement, October 2020. $8.3 billion in penalties.
3. In re: Purdue Pharma L.P., et al., U.S. Bankruptcy Court Southern District of New York, filed September 2019. Reorganization plan documents.
4. Harrington, U.S. Trustee v. Purdue Pharma L.P., U.S. Supreme Court ruling, June 27, 2024 (603 U.S. ___).
5. McKinsey & Company multi-state settlement, February 2021. $573 million.
6. Porter & Jick, "Addiction Rare in Patients Treated with Narcotics," NEJM, January 10, 1980. The five-sentence letter that became Purdue's foundational marketing citation.

Secondary investigative reporting: 7. Patrick Radden Keefe, Empire of Pain: The Secret History of the Sackler Dynasty (Doubleday, 2021). The definitive single-volume Sackler family history. 8. Beth Macy, Dopesick: Dealers, Doctors, and the Drug Company That Addicted America (Little, Brown, 2018). 9. Sam Quinones, Dreamland: The True Tale of America's Opiate Epidemic (Bloomsbury, 2015). 10. Barry Meier, Pain Killer: An Empire of Deceit and the Origin of America's Opioid Epidemic (Random House, 2003, revised 2018). 11. Patrick Radden Keefe, "The Family That Built an Empire of Pain," The New Yorker, October 30, 2017. 12. Walt Bogdanich & Michael Forsythe, "How McKinsey Helped Purdue Pharma Sell More OxyContin," The New York Times, November 27, 2020. 13. ProPublica, multi-year Purdue investigation, particularly Susan Glasser. 14. 60 Minutes, "Tracking the Opioid Crisis," CBS, January 22, 2017.

Academic / scientific scholarship: 15. Andrew Kolodny et al., "The Prescription Opioid and Heroin Crisis: A Public Health Approach to an Epidemic of Addiction," Annual Review of Public Health, 2015. 16. CDC, Annual Surveillance Report of Drug-Related Risks and Outcomes — United States, multiple years 2017-2024. 17. Nora Volkow & A. Thomas McLellan, "Opioid Abuse in Chronic Pain — Misconceptions and Mitigation Strategies," NEJM, 2016.

Corrections & updates

2026-05-26: First publication.